AI-Powered Virtual Tumor Boards Democratize Access to Expert Cancer Analysis with Steve Brown and Lisa Booth CureWise TRANSCRIPT
Release Date: 02/04/2026
AI-Powered Virtual Tumor Boards Democratize Access to Expert Cancer Analysis with Steve Brown and Lisa Booth CureWise TRANSCRIPT
Empowered Patient Podcast
Steve Brown, Founder and CEO and Lisa Booth, Vice President of Operations of CureWise, are both cancer survivors, which led them to develop an AI-powered tumor board platform to advance cancer diagnoses and treatment. This approach to precision medicine provides patients with the opportunity to better understand their specific condition, educating them about possible courses of action that may be more appropriate than the standard of care. The platform also helps patients find relevant clinical trials and manage the side effects of their treatments. Steve explains, "So the mission...
info_outline
AI-Powered Virtual Tumor Boards Democratize Access to Expert Cancer Analysis with Steve Brown and Lisa Booth CureWise
Empowered Patient Podcast
Steve Brown, Founder and CEO and Lisa Booth, Vice President of Operations of CureWise, are both cancer survivors, which led them to develop an AI-powered tumor board platform to advance cancer diagnoses and treatment. This approach to precision medicine provides patients with the opportunity to better understand their specific condition, educating them about possible courses of action that may be more appropriate than the standard of care. The platform also helps patients find relevant clinical trials and manage the side effects of their treatments. Steve explains, "So the mission...
info_outline
Effectively Treating Rare Epileptic Disorder Dravet Syndrome with Nayla Chaijale UCB TRANSCRIPT
Empowered Patient Podcast
Nayla Chaijale, Medical Strategy Lead for Rare Syndromes at UCB, describes Dravet syndrome, a rare, medication-resistant epileptic encephalopathy that involves seizures and significant co-morbidities like cognitive and developmental delays. Their approved drug FINTEPLA has a unique mechanism of action that modulates pathways in the brain and has demonstrated a significant reduction in the frequency of convulsive seizures in those with this condition. Nayla notes that the good news is that most patients with Dravet syndrome have a mutation in the SCN1A gene, a critical biomarker that...
info_outline
Effectively Treating Rare Epileptic Disorder Dravet Syndrome with Nayla Chaijale UCB
Empowered Patient Podcast
Nayla Chaijale, Medical Strategy Lead for Rare Syndromes at UCB, describes Dravet syndrome, a rare, medication-resistant epileptic encephalopathy that involves seizures and significant co-morbidities like cognitive and developmental delays. Their approved drug FINTEPLA has a unique mechanism of action that modulates pathways in the brain and has demonstrated a significant reduction in the frequency of convulsive seizures in those with this condition. Nayla notes that the good news is that most patients with Dravet syndrome have a mutation in the SCN1A gene, a critical biomarker that...
info_outline
AI Platform Facilitating Improved Accessibility to Clinical Trials with Vanessa Lemarié myTomorrows TRANSCRIPT
Empowered Patient Podcast
Vanessa Lemarié, Chief Operations Officer at myTomorrows, which is a platform for connecting patients, physicians, and clinical trial sponsors using a Trial Search AI tool designed to improve the accuracy of matching patients with suitable trials. The technology aims to speed up trial recruitment, increase diversity by reaching underserved populations, and ultimately shorten the drug development timeline. There is a particular focus on patients with no treatment options or who have not responded to current therapies. Vanessa explains, "We are all about patients. First and foremost, we want...
info_outline
AI Platform Facilitating Improved Accessibility to Clinical Trials with Vanessa Lemarié myTomorrows
Empowered Patient Podcast
Vanessa Lemarié, Chief Operations Officer at myTomorrows, which is a platform for connecting patients, physicians, and clinical trial sponsors using a Trial Search AI tool designed to improve the accuracy of matching patients with suitable trials. The technology aims to speed up trial recruitment, increase diversity by reaching underserved populations, and ultimately shorten the drug development timeline. There is a particular focus on patients with no treatment options or who have not responded to current therapies. Vanessa explains, "We are all about patients. First and foremost, we want...
info_outline
Providing Access to Uncovered Specialty Medications with Paul Pruitt SHARx TRANSCRIPT
Empowered Patient Podcast
Paul Pruitt, Chief Growth Officer at SHARx, which is a company that partners with employers to provide access to drugs not covered by insurance, such as specialty medications. The SHARx model acts as a complementary service to existing Pharmacy Benefit Managers and allows employers to opt out of covering the most expensive drugs. Paul's personal experience managing his sons' rare condition and navigating the administrative burden and frustration of the insurance system gives him deep insights into the factors driving up the cost of medications. Paul explains, "When we started SHARx eight...
info_outline
Providing Access to Uncovered Specialty Medications with Paul Pruitt SHARx
Empowered Patient Podcast
Paul Pruitt, Chief Growth Officer at SHARx, which is a company that partners with employers to provide access to drugs not covered by insurance, such as specialty medications. The SHARx model acts as a complementary service to existing Pharmacy Benefit Managers and allows employers to opt out of covering the most expensive drugs. Paul's personal experience managing his sons' rare condition and navigating the administrative burden and frustration of the insurance system gives him deep insights into the factors driving up the cost of medications. Paul explains, "When we started SHARx eight...
info_outline
AI-Powered Diagnostics and Targeted Radiotherapy for CNS Cancers with Dr. Marc Hedrick Plus Therapeutics TRANSCRIPT
Empowered Patient Podcast
Dr. Marc Hedrick, President and CEO of Plus Therapeutics Inc., has expanded their focus from glioblastoma to leptomeningeal metastasis, a central nervous system cancer that is a growing challenge due to increased survival rates from primary cancers. Their highly sensitive, advanced diagnostic test, CNSide, can detect cancer cells in cerebrospinal fluid, addressing the shortcomings of imaging and outdated standard-of-care practices. Using AI and advanced data analytics, their lead drug candidate is uniquely suited for treating CNS cancers because its safety at high doses enables the...
info_outline
AI-Powered Diagnostics and Targeted Radiotherapy for CNS Cancers with Dr. Marc Hedrick Plus Therapeutics
Empowered Patient Podcast
Dr. Marc Hedrick, President and CEO of Plus Therapeutics Inc., has expanded their focus from glioblastoma to leptomeningeal metastasis, a central nervous system cancer that is a growing challenge due to increased survival rates from primary cancers. Their highly sensitive, advanced diagnostic test, CNSide, can detect cancer cells in cerebrospinal fluid, addressing the shortcomings of imaging and outdated standard-of-care practices. Using AI and advanced data analytics, their lead drug candidate is uniquely suited for treating CNS cancers because its safety at high doses enables the...
info_outlineSteve Brown, Founder and CEO and Lisa Booth, Vice President of Operations of CureWise, are both cancer survivors, which led them to develop an AI-powered tumor board platform to advance cancer diagnoses and treatment. This approach to precision medicine provides patients with the opportunity to better understand their specific condition, educating them about possible courses of action that may be more appropriate than the standard of care. The platform also helps patients find relevant clinical trials and manage the side effects of their treatments.
Steve explains, "So the mission really is to harness AI to advance cancer care. And ultimately, for that reason, anybody who's touched by cancer is hopeful that we will be making more progress toward cures for cancer. And we believe that that's going to happen through precision medicine, which really means recognition that everybody's cancer is unique. And at some point, we're going to treat cancer that way because we're going to know enough about how it all works. We're going to be able to individualize care. So our mission is to advance that cause."
Lisa elaborates, "When Steve and I started working together, one of the things I said was that I needed a way as a patient to be able to access different perspectives of a radiologist, an interventional radiologist, a pathologist, a geneticist, an oncologist, etc. And I can get that in Seattle, but most of the people I work with can't, meaning the patients and my friends in the cancer community don't have access to that because they don't exist in their communities."
#CancerCare #AI #PrecisionMedicine #PatientEmpowerment #HealthTech #CancerSurvivors #DigitalHealth #Oncology #TumorBoard #ClinicalTrials #HealthcareInnovation #PatientAdvocacy #PatientLedInnovation #CancerAndAI #TumorBoardTech #AIForPatients #SteveBrownAI #LisaBoothSurvivor #MedicalAutonomy #HealthTechWithHeart #NOfOneMedicine
